Cargando…

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

BACKGROUND: Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bozorgmehr, Farastuk, Hommertgen, Adriane, Krisam, Johannes, Lasitschka, Felix, Kuon, Jonas, Maenz, Martin, Huber, Peter E., König, Laila, Kieser, Meinhard, Debus, Juergen, Thomas, Michael, Rieken, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842256/ https://www.ncbi.nlm.nih.gov/pubmed/31703637 http://dx.doi.org/10.1186/s12885-019-6205-0

Ejemplares similares

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial
por: Kuon, Jonas, et al.
Publicado: (2020)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2020)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2023)

Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study
por: Liermann, Jakob, et al.
Publicado: (2020)

Whole brain radiation therapy alone versus radiosurgery for patients with 1–10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial
por: Bernhardt, Denise, et al.
Publicado: (2018)

Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial
por: Arians, Nathalie, et al.
Publicado: (2020)

Optimal Decision Rules for Biomarker-Based Subgroup Selection for a Targeted Therapy in Oncology
por: Krisam, Johannes, et al.
Publicado: (2015)

Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy
por: Bernhardt, Denise, et al.
Publicado: (2018)

Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy
por: Fink, Christoph A., et al.
Publicado: (2023)

Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
por: Bernhardt, Denise, et al.
Publicado: (2018)

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2022)

Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial
por: Hauswald, Henrik, et al.
Publicado: (2015)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial
por: Brügemann, D., et al.
Publicado: (2022)

Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy—GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study
por: König, Laila, et al.
Publicado: (2021)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes
por: Eichkorn, Tanja, et al.
Publicado: (2023)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Mini-ethnography for medical students. Inquiry-based learning to foster transcultural competences
por: Ziegler, S, et al.
Publicado: (2023)

Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
por: Combs, Stephanie E, et al.
Publicado: (2010)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients
por: von Eiff, Damian, et al.
Publicado: (2020)

Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial
por: Held, Thomas, et al.
Publicado: (2020)

Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy
por: Haefner, Matthias F., et al.
Publicado: (2015)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

COMPARE Family (Children of Mentally Ill Parents at Risk Evaluation): A Study Protocol for a Preventive Intervention for Children of Mentally Ill Parents (Triple P, Evidence-Based Program That Enhances Parentings Skills, in Addition to Gold-Standard CBT With the Mentally Ill Parent) in a Multicenter RCT—Part II
por: Stracke, Markus, et al.
Publicado: (2019)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer—Experiences from a Single Institution
por: Hörner-Rieber, Juliane, et al.
Publicado: (2017)

On Foster-- Foster on /
Publicado: (2000)

Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study
por: Rochet, Nathalie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_04j6kbb4at41ajfudf3vteebfa